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The locations of transcriptional enhancers and promoters were recently mapped in many
mammalian cell types. Proteins that bind those regulatory regions can determine cell identity
but have not been systematically identiﬁed. Here we purify native enhancers, promoters or
heterochromatin from embryonic stem cells by chromatin immunoprecipitations (ChIP) for
characteristic histone modiﬁcations and identify associated proteins using mass spectrometry
(MS). 239 factors are identiﬁed and predicted to bind enhancers or promoters with different
levels of activity, or heterochromatin. Published genome-wide data indicate a high accuracy
of location prediction by ChIP-MS. A quarter of the identiﬁed factors are important
for pluripotency and includes Oct4, Esrrb, Klf5, Mycn and Dppa2, factors that drive
reprogramming to pluripotent stem cells. We determined the genome-wide binding sites of
Dppa2 and ﬁnd that Dppa2 operates outside the classical pluripotency network. Our ChIP-MS
method provides a detailed read-out of the transcriptional landscape representative of the
investigated cell type.
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A
mammalian genome supports the generation of the
hundreds of different cell types in an organism. These cell
types display distinct gene expression proﬁles as a direct
consequence of differences in the activation state of their gene
promoters and distal cis-regulatory elements called transcrip-
tional enhancers. The ENCODE project has generated a wealth of
data on the genome-wide chromatin landscape of many different
mouse and human cell types1,2. In particular, the genome-wide
identiﬁcation of regulatory regions such as transcriptional
enhancers and promoters and their state of activity has the
potential to increase our understanding of how cell type identity
is acquired and maintained. From reprogramming experiments it
has become increasingly clear that the identity of cells is to a large
extent determined by transcription factors, which bind enhancers
and promoters3–6. It is therefore of interest to purify native
transcriptional enhancers and promoters of a given cell type and
identify the proteins that bind to these regulatory regions.
Here we performed chromatin immunoprecipitations (ChIP) for
histone modiﬁcations associated with promoters, enhancers or
heterochromatin in mouse embryonic stem cells (ESCs) and
identiﬁed the proteins present in the different precipitated
fractions by mass spectrometry (MS), a method that we named
ChIP-MS.
Our ChIP-MS experiments identiﬁed 239 factors that we could
predict to bind to promoters, enhancers or heterochromatin.
Among these factors are subunits of several chromatin-modifying
complexes and proteins that play a role in different aspects of
transcriptional regulation. We also ﬁnd key ESC transcription
factors such as Oct4, Esrrb, Dppa2 and Klf5 that are not only
important for maintaining ESC self-renewal but also facilitate the
reprogramming of somatic cells to induced pluripotent stem
cells (iPSCs)4,7–9. Genome-wide data sets were available for
28 ChIP-MS-identiﬁed factors and correlated well with the
ChIP-MS-based predictions for these factors, suggesting a high
level of accuracy of location prediction by ChIP-MS.
For many of the detected factors, the genome-wide localization
has not yet been determined and our ChIP-MS results provide the
ﬁrst evidence of their binding preference for a particular type of
regulatory DNA. To illustrate that ChIP-MS can identify factors
with an interesting genome-wide location, we determined
the genome-wide binding sites of pluripotency marker and
reprogramming factor Dppa2. We show that Dppa2 is not part of
the classical pluripotency transcriptional network and that Dppa2
target genes reach full activation only later in development.
Results
ChIP-MS rationale and procedure. Transcriptional enhancers
and promoters can be recognized by the chemical modiﬁcations
of their associated histones, especially histone H3. Promoters
of transcribed genes were found to contain histone H3 tri-
methylated at lysine 4 (H3K4me3)10,11 and the level of their
activity correlates with the level of H3K27 acetylation (H3K27ac)
present12,13. Enhancers contain histone H3 mono-methylated at
lysine 4 (H3K4me1)14 and active enhancers can be recognized
by the presence of the H3K27ac mark15,16. Inactive
(hetero)chromatin is marked by H3K9me3 (ref. 17). The
presence or absence of these and other chromatin marks was
used to postulate ﬁfteen different chromatin regions in the
mammalian genome, including promoters and enhancers with
different levels of activity13.
We anticipated that ChIP for H3K4me3 would precipitate
active promoters and ChIP for H3K4me1 would precipitate
enhancers. ChIP for H3K27ac would preferentially
precipitate the most active promoters and enhancers, whereas
ChIP for H3K9me3 would precipitate heterochromatin. Accord-
ingly, we performed large-scale ChIPs in biological duplicate for
H3K4me3, H3K4me1, H3K27ac or H3K9me3, and for green
ﬂuorescent protein (GFP) as a control, in mouse ESCs (Fig. 1a,b).
Crosslinking of the chromatin was performed with Disuccinimi-
dyl glutarate (DSG), a protein–protein crosslinker, followed by
standard formaldehyde crosslinking, to increase the crosslinking
efﬁciency of genome-bound factors to the chromatin18–20. ChIP
wash steps were performed in low-adherence tubes to increase
protein yield and reduce background20,21. Bound protein
factors were de-crosslinked and eluted by prolonged heating
in protein denaturing conditions, separated on an
SDS–polyacrylamide gel, tryptic peptides isolated and analysed
by MS. A representative protein gel showed the (unresolved)
histones precipitated with each histone modiﬁcation antibody but
not with the GFP control (Fig. 1c). Analysis by western blot
revealed that comparable amounts of chromatin were precipitated
in the different histone-modiﬁcation ChIPs, as indicated by the
total content of histone H3 (Fig. 1d). ChIP against H3K4me1,
H3K4me3 or H3K27ac precipitated chromatin with these
respective histone modiﬁcations (Fig. 1d). Minor amounts of
H3K4me1 were observed in the H3K4me3 ChIP and vice-versa.
This is to be expected as H3K4me1 is present at low levels around
active promoters15. H3K9me3 ChIP precipitated H3K9me3-
marked chromatin but no signiﬁcant amounts of the other
histone modiﬁcations (Fig. 1d). We conclude that the histone
modiﬁcation ChIPs efﬁciently precipitated the intended
chromatin fractions.
Subsequently, we tested whether our modiﬁed ChIP protocol,
which we use for ChIP-MS, still precipitated the intended
genomic regions, as compared with conventional ChIP. DNA
precipitated by modiﬁed ChIP for the different histone
modiﬁcations was sequenced (ChIP-seq) and mapped to the
genome. DNA precipitated by modiﬁed ChIP correlated well with
the corresponding published conventional ChIP-seq for all four
histone modiﬁcations (Fig. 1e). Modiﬁed H3K4me3 ChIP
predominantly precipitated promoters and modiﬁed H3K4me1
ChIP precipitated predominantly enhancers, as intended (Fig. 1f).
Examples of histone modiﬁcation tracks around pluripotency
genes Tcfcp2l1 (Fig. 1g) and Nanog (Supplementary Fig. 1) show
high similarity between our modiﬁed ChIP and conventional
ChIP. We conclude that the inclusion of additional crosslinker
DSG has not signiﬁcantly altered the genomic regions
precipitated by our ChIP protocol, as compared with conven-
tional ChIP.
Prediction of genome localization of identiﬁed factors.
We analysed the different precipitated chromatin fractions and
GFP control fractions by MS for an unbiased identiﬁcation of the
protein factors present in each fraction. We identiﬁed 249 factors
that have at least a threefold difference in Exponentially Modiﬁed
Protein Abundance Index (emPAI) score, a measure for the
amount of protein present22, in the ChIPs for one histone
modiﬁcation compared with the ChIPs for one or more of the
other histone modiﬁcations. Included factors should have no or
very low presence (more than ﬁvefold lower emPAI score) in any
of the GFP control ChIPs (Supplementary Tables 1 and 2,
and Supplementary Methods). These two selection steps
were included to exclude proteins that bind to chromatin
indiscriminately of the tested histone modiﬁcations, or are
background of the ChIP-MS procedure, respectively. Of the 249
factors, 10 factors were only present in the H3K27ac fraction,
which does not discriminate between promoters and enhancers,
leaving 239 factors for which we could predict their binding
to promoters, enhancers or heterochromatin. We assigned
to identiﬁed factors the locations ‘promoter’, ‘enhancer’ and
‘heterochromatin’ according to the fraction (H3K4me3,
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H3K4me1 and H3K9me3, respectively) in which they have the
highest emPAI value (Supplementary Tables 1, 2 and 3, and
Supplementary Methods). This annotation is not absolute, as
factors can be present in more than one location, but it does
provide clarity and facilitates a more systematic validation with
published genome-wide localization data (see below).
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Figure 1 | Outline and initial validation of the ChIP-MS protocol. (a) Flowchart of the ChIP-MS protocol. (b) Histone modiﬁcations used in ChIP-MS and
their predominant location on the genome. (c) Representative 10% polyacrylamide gel with proteins from ChIPs for the indicated histone modiﬁcations and
the GFP control ChIP. Arrows indicate unresolved histones in the histone modiﬁcation ChIPs, which are absent in the GFP control ChIP. Molecular weight
markers are depicted by M. (d) Western blot analyses of the histone modiﬁcation content, histone content and the presence of Nanog in the
immunoprecipitated chromatin fractions. Different ChIPs are indicated at the top, antibodies used for the different western blot analyses are on the right.
(e) Correlation between DNA regions precipitated by modiﬁed ChIP and conventional ChIP for H3K4me3, H3K27ac, H3K4me1 or H3K9me3. (f) Overlap of
DNA precipitated with modiﬁed ChIP for H3K4me3, H3K4me1 or H3K27ac with promoters and enhancers. Number of ChIP-seq reads overlapping with
promoters or enhancers is indicated. (g) ChIP-seq tracks for modiﬁed ChIP or conventional ChIP for H3K4me3, H3K4me1 or H3K27ac around pluripotency
gene Tcfcp2l1. Sequence reads were plotted relative to chromosomal position. Genome location of Tcfcp2l1 is shown, scale bar indicates 5 kb of genome.
P indicates promoter, E indicates putative enhancer.
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We also indicated the presence of a factor in the H3K27Ac
fractions by calculating the ratio of its average emPAI value in the
H3K27ac fractions over its H3K4me3 emPAI score or its
H3K4me1 emPAI score, whichever one is the highest, a ratio
that we call the H3K27ac ratio. Presenting the ChIP-MS
association of a factor with the H3K27ac modiﬁcation in this
way compensates for the considerable differences in ChIP-MS
detection levels for different proteins (Supplementary Table 1)
and is therefore more informative than its H3K27ac emPAI value
per se. Small emPAI values for H3K4me3 or H3K4me1 increase
the uncertainty of the H3K27ac ratio value. We used the
H3K27ac ratio as a predictor for the level of H3K27ac, and
thereby the activity, of the promoters or enhancers bound by the
factor (Supplementary Table 1).
For a visual representation (Fig. 2), identiﬁed factors and
complexes were allocated according to their predicted binding to
promoters, enhancers or heterochromatin. The calculated
H3K27ac ratios were used to position predicted enhancer-binding
factors on the upper horizontal axis reﬂecting the level of activity
of bound enhancers or position-predicted promoter binders on
the right vertical axis reﬂecting the level of activity of bound
promoters (Fig. 2).
An early indication that the predictions from our ChIP-MS
experiments were valid came from the ‘promoter’ prediction of all
ﬁve identiﬁed RNApol2 subunits and seven identiﬁed TFIID
subunits (Supplementary Table 3). The H3K9 methyltransferase
Suv3-9 binds pericentric heterochromatin23 and was indeed
observed solely in the H3K9me3 fraction (‘heterochromatin’
prediction, Fig. 2 and Supplementary Table 1). We identiﬁed a
large number of subunits of established chromatin-modifying
complexes including the BAF complex, Sin3 complex and MLL
complex (Fig. 2 and Supplementary Table 3). Strikingly, the
localization prediction for different subunits within the same
complex was nearly 100% identical (Supplementary Table 3),
indicating a high level of consistency in the predictions.
Among the ChIP-MS identiﬁed factors with the highest
H3K27ac ratio, predicting binding to highly active regulatory
regions, were chromatin factors of the BET family: Brd2, 3 and 4
(Fig. 2 and Supplementary Table 1). BET family members were
shown to bind to hyperacetylated chromatin24. Brd4 was recently
identiﬁed as a key factor in the marking and functional
maintenance of exceptionally large and active ‘super enhancers’,
which regulate the expression of cell fate-determining genes25,26.
ChIP-MS classiﬁed Brd4 to bind predominantly to enhancers and
Enhancer
Prom
oter
Heterochromatin
Weak Strong Strong
W
e
ak
Gtf3c1 Tead1 Cdca7Rsf1Nacc1Srrt Phip Ssrp1
Baz2a
BAF
Cul4b Zmynd8
Klf5
Tcerg1
Esrrb Taldo1 Mta3
Cep95PRC2
Pin1
Kifc5b
Pds5a Cohesin Ddb1 Dis3Usp48 Pds5b
Lig3
Mdc1
Nasp
Numa1
Atad2b
Uba1Chaf1b Dnajc9
Glyr1
Gtf2i Nsd1
Trim24
Tcea1
Brd3
Brd4
Rfc3
Ogt
Kdm5b
Spin1
Kdm4c
Morc3
Kdm1a
DSIF
Hdac1
Phf8
Kdm2a
Trrap/Ep400
Supt6h
Brd2
INO80
Prdm10
Mycn
Max
Ing3
Cpsf6
Csnk2b
Csnk2a1
Shprh
Bptf
Sephs1
Hat1
Chd8
MLL
Sin3
Dppa2
Rbbp4
Ubtf
Dut
RNApol2
Skp1a
Actl6a
TFIID
Ctbp2
Banf1
Rcf4
Chd1 Cdc73
Ctr9
H3K9me3
Atrx
Tcof1
Suv39h2
Ddx47
Aurora K
Hmga2
Parp9 Lmna
Znf512Coil
Lmnb2
Lrwd1
Lmnb1Anln Kdm4a
Csrp2bp
Emsy
Cse1l Dido1
Kdm5a
PRC1
Chd2
Qser1Rbpj
Hdac2
Kdm2b
Psma5Hmgb3
H3K4me3
Klf16
Cdk7Ckb
Hmgxb4Wdr55
Cald1
Zic5
Zfp280c
Dppa4
L3mbtl2
Zfp462
Lasp1
Patz1
Ctcf
Bend3
Lig1
Smchd1
Phf23
Mbtd1
Nudt21
Nrf1Creb1
Polr1cErh
Pnp
Actr3
Sf1
Fbxl19 Rars
Zfp281
Pak1ip1Gm53
Samd1
Adnp
Vmn2r100 Zscan10Wdr18
Hp1bp3 Anp32a
H3K4me1
Kif2c
Fkbp4 Ptcd3
Nudt13
Llph
Nolc1
Gltscr2
Ube2h Gtf2e1
Tbrg4
Las1l
Luc7l3Prdm2 CadAnkhd1 Prrc2cUtp14b Sf3b1Ppp2cb
Ddx54
Cdc5l
Irgc Rbl1
Parp2
Baz1a
Phf20
Kif4
Sbno1
Tlk2
Smc6
Ints1
H3K27Ac
Oct4
HBO1/
MOZ/MORF
H e1
e3 H e3
H3 ac
Figure 2 | ChIP-MS predicted locations of identiﬁed factors and complexes. Visual representation of factors (small orange circles) and complexes (large
orange circles) identiﬁed by ChIP-MS for four different histone modiﬁcations (blue squares). Thickness of the edges indicates average emPAI score of a
factor or complex in histone modiﬁcation ChIP. Factors and complexes are positioned according to their ChIP-MS location prediction. To the left of the
yellow dashed line are predicted enhancer binders, positioned horizontally from weak activity enhancers (left) to strong activity enhancers (right) according
to their H3K27ac ratio. To the right of the yellow dashed line are predicted promoter binders positioned vertically from weak activity promoters (bottom) to
strong activity promoters (top) according to their H3K27ac ratio. In the left bottom square are factors and complexes predicted to bind heterochromatin.
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Brd2 and 3 to bind promoters. Using ChIP-seq, Brd2 and Brd3
were indeed shown to bind promoters, whereas Brd4 was also
present at enhancers27. The ﬁnding that from all ChIP-MS
detected proteins, several BET family members are among the
proteins with the highest H3K27ac ratio, validates the use of the
H3K27ac ratio as an indicator of the level of activity of bound
promoters or enhancers.
Many studies have identiﬁed factors that are important for
maintaining ESC pluripotency28–30 or factors that reprogramme
somatic cells towards ESC-like iPSCs4,6,7. We found that more
than a quarter of our ChIP-MS identiﬁed factors (63 out of 239)
have a role in pluripotency acquisition or maintenance
(Supplementary Table 1). ChIP-MS-identiﬁed factors included
established reprogramming factors Oct4, Esrrb, Klf5 and Mycn
(Fig. 2 and Supplementary Table 1), which as part of a 3–4 factor
mix, reprogramme somatic cells to iPSCs4,7,8. Our ChIP-MS data
predicted that Oct4, Esrrb and Klf5 bind predominantly to
enhancers and Mycn predominantly binds to promoters, in
agreement with published genome localization data3,31. Nanog,
another well-known pluripotency factor, is difﬁcult to detect by
MS21,32 and was indeed not identiﬁed by ChIP-MS. Western blot
analysis of our ChIP-MS samples showed that Nanog was present
in the H3K4me1 fraction (Fig. 1d), suggesting it binds to
enhancers, in agreement with published data3.
Estimation of ChIP-MS prediction accuracy. Our list of 239
ChIP-MS assigned factors includes 28 factors for which the
genome-wide binding sites have been determined in mouse ESCs
by ChIP-seq (Fig. 3a), which provides an opportunity to probe
the accuracy of our localization prediction. In a ﬁrst analysis, we
compared our ChIP-MS-based predictions (Fig. 3a) with location
predictions derived from the correlation of factor binding sites
with the different histone marks on the genome (Fig. 3a). Of the
17 factors predicted by ChIP-MS to be promoter associated,
14 factors (82%) were indeed most associated on the genome with
the active promoter mark H3K4me3 (Fig. 3a). In the case of Ctr9,
Ctcf and Cbx7, the ChIP-MS prediction were not conform the
location prediction by genome-wide correlation. However, in
these cases both the ChIP-MS values and genome-wide correla-
tions for H3K4me3 and H3K4me1 (which differentiates between
‘promoter’ and ‘enhancer’ prediction) were very similar (Fig. 3a).
Moreover, the correlation with any of the four tested histone
marks was low for Ctcf and Cbx7.
Of the ten factors predicted by ChIP-MS to be predominantly
associated with enhancers, six had indeed the highest association
on the genome with enhancer mark H3K4me1 (Fig. 3a). These
include Oct4 and Esrrb, two key pluripotency and reprogram-
ming transcription factors, and Smarca4 (Brg1), the catalytic
subunit of the SWI-SNF chromatin-modifying complex (Fig. 3a).
All the wrongly annotated factors (Suz12, Jarid2, Mtf2, Ezh2) are
members of the Polycomb family of repressor proteins, which had
‘Enhancer’ ChIP-MS predictions but were assigned ‘Promoter’ by
the genome-wide correlation of their binding sites (Fig. 3a).
Polycomb factors are abundant in ESCs and often bind broadly
at relatively inactive promoters with similarly low levels of
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Figure 3 | Validation of ChIP-MS predictions with published genome-
wide location information. (a) Comparison of location prediction by
ChIP-MS with location prediction by correlation of genome-wide binding
sites with the indicated histone modiﬁcations on the genome. Protein
factors for which genome-wide locations in mouse ESCs are determined by
ChIP-seq are listed on the left, according to their ChIP-MS prediction as
promoter binder (top, green panel), enhancer binder (middle, blue panel) or
heterochromatin binder (bottom, red panel). Indicated in columns from left
to right are: protein factor, its average emPAI values in the different histone
modiﬁcation ChIPs, its H3K27ac ratio (if highest emPAI valueZ0.1),
ChIP-MS location prediction, correlation of genome-wide binding sites with
the indicated histone modiﬁcations and location prediction by highest
correlation with a histone modiﬁcation, according to Fig. 1b. (b) Binding
of selected protein factors to promoters and enhancers in mouse ESCs.
Heatmaps of 12,913 promoters (upper panel) or 30,564 enhancers (lower
panel), centred on H3K4me3 signal (Promoters) or H3K4me1 signal
(Enhancers), ranked on H3K27ac content from top to bottom. Displayed is
8 kb around the centre of the promoter or enhancer. Normalized ChIP-seq
reads representing the level of H3K4me1, H3K27ac and H3K4me3 histone
modiﬁcations are indicated in the ﬁrst three lanes. Normalized ChIP-seq
reads representing relative binding intensity to promoters (upper panel)
and enhancers (lower panel) of protein factors from a (highest emPAI value
Z0.1) are displayed in lanes 4–12 and 14–20. Factors are arranged
according to binding prediction or Polycomb factor identity. *p300 was not
predicted by ChIP-MS but its genome-wide location was included in lane
13 for comparison.
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H3K4me3 and H3K4me1 (see below)33,34. Both histone marks
are indeed faithfully detected by ChIP-MS but in the above cases
this leads to wrong predictions, albeit by small margins in the
H3K4me3 and H3K4me1 ChIP-MS values (Fig. 3a). Atrx was
correctly assigned by ChIP-MS to bind H3K9me3-containing
heterochromatin (Fig. 3a). We conclude from this analysis that
ChIP-MS predicted factor location to promoters, enhancers
or heterochromatin with high accuracy, with the few false
identiﬁcations in the expected grey areas.
Subsequently, we assessed whether the H3K27ac ratio of a
factor correlates with the association of its binding sites with
H3K27ac on the genome (Fig. 3a). From the factors with genome-
wide location information (Fig. 3a), we took factors with a highest
emPAI value of 0.1 or higher, to be well above the detection limit
of our ChIP-MS experiments. We calculated for each of these
factors their H3K27ac ratio (Fig. 3a). These ratios were compared
with the correlation of genome-wide binding of these factors with
H3K27ac-marked regions (Fig. 3a). Indeed, promoter-predicted
factors Tcea1, Polr2a and Supt5h have the highest H3K27ac ratios
and have relatively high correlations with H3K27ac on the
genome (Fig. 3a). Promoter-predicted factors Hdac1 and 2,
Kdm5b, Rnf2 and Cbx7 have low H3K27ac ratios and are factors
with relatively low genome-wide associations with H3K27ac
(Fig. 3a). Kdm2a and Rbbp5 have low H3K27ac ratios but still
have high genome-associations with H3K27ac. Hence, in these
two cases, the H3K27ac ratios do not correlate well with H3K27ac
association on the genome. Brd4 is the enhancer-predicted factor
with the highest H3K27ac ratio and indeed has the highest
correlation with H3K27ac on the genome (Fig. 3a). Oct4, Esrrb
and Smc1a have intermediate H3K27ac ratios and intermediate
genome-wide association with H3K27ac. Smarca4 has a high
H3K27ac ratio, which in this case was not a good predictor, as
Smarca4 has an intermediate level of genome-wide association
with H3K27ac. We conclude from our above analyses that
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Heatmaps of 12,913 promoters (left panel) or 30,564 enhancers (right panel), centred on H3K4me3 signal (Promoters) or H3K4me1 signal (Enhancers),
ranked on H3K27ac content from top to bottom. Displayed is 8 kb around the centre of the promoter or enhancer. Normalized ChIP-seq reads representing
the level of H3K4me1, H3K27ac and H3K4me3 histone modiﬁcations are indicated in the ﬁrst three lanes. Normalized V5-Dppa2 ChIP-seq reads
representing the relative binding intensity of Dppa2 to promoters (left panel) and enhancers (right panel) are displayed in the fourth lane of each panel.
(e) Distribution of absolute expression levels of H3K4me3 marked genes in mouse ESCs that (from left to right) are bound at the promoter by Dppa2,
all genes, and bound within 20 kb around the promoter by Oct4. Shown is a violin plot where the white dot indicates the median and the thick black
bar indicates 50% of the genes. Log2 value of the absolute expression, derived from published RNAseq data, the number of genes in each category and
P-values by Mann–Whitney test are indicated.
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H3K27ac ratios provide a good, albeit not ﬂawless, indication of
the level of localization to H3K27ac-marked regions on the
genome.
In a second approach to assess the accuracy of ChIP-MS, we
investigated the presence of the above factors at promoters and
enhancers in mouse ESCs. We assigned promoters as being
present at the start of a gene and containing H3K4me3.
Enhancers were assigned by their H3K4me1 content in the
absence of H3K4me3. Promoters and enhancers were ranked top
to bottom by their H3K27ac content (Fig. 3b). Promoter-
predicted factors Kdm2a, Rbbp5, Polr2a, Wdr5, Tcea1, Supt5h
and Kdm5b were indeed observed to only bind promoters and
not enhancers (Fig. 3b). Hdac1 and Hdac2 predominantly bound
to promoters but also showed binding to enhancers. Enhancer-
predicted factors Esrrb, Oct4, Brd4 and Smc1a all showed strong
binding to enhancers (Fig. 3b). These factors also showed binding
to promoters to varying degrees. For comparison, we also
included published genome-wide localization data of archetypal
enhancer binder p300 in Fig. 3b. Remarkably, p300 showed
binding to enhancers and promoters (Fig. 3b), as previously
observed in human ESCs33. Polycomb factors Rnf2, Jarid2, Suz12,
Cbx7 and Mtf2 bind promoters with no correlation (Rnf2, Jarid2)
or an anti-correlation (Cbx7, Suz12 and Mtf2) for H3K4me3 and
H3K27ac content (Fig. 3b). The broad binding of Polycomb
factors to promoters with relatively low H3K4me3 levels
would explain their similar ChIP-MS values for H3K4me3
and H3K4me1 (Fig. 3a) and the associated ChIP-MS
prediction uncertainties. The above analysis suggests that
ChIP-MS-mediated prediction of binding to promoters or
enhancers has high accuracy, with Polycomb factors again
being an exception.
Dppa2 is not part of the classical ESC pluripotency network.
For many of the ChIP-MS detected factors, the genome locali-
zation has not yet been determined by genome-wide ChIP and
our experiments provide the ﬁrst information on their genome
binding preferences. As an example that ChIP-MS can identify
factors with an unusual and therefore interesting genomic dis-
tribution, we focused on Dppa2 (Developmental PluriPotency
Associated 2). Dppa2 is a member of family that also contains
Dppa3 (Stella) and Dppa4, which all harbour a SAP DNA-
binding domain. The genome-wide binding sites of members of
this family have not been determined so far. Dppa2 is exclusively
expressed in the inner cell mass of the early embryo and later in
the developing germ line and in cells derived from these tissues,
such as ESCs and primordial germ cells35. Furthermore, Dppa2
expression was identiﬁed as an early marker for successful
reprogramming towards iPSCs9. Dppa2 knockout ESCs have a
slower proliferation rate and Dppa2 knockout mice die after birth
from respiratory defects36. Recently, it was shown that Dppa2,
in combination with Lin28, Sall4 and Esrrb, drives the
reprogramming of ﬁbroblasts into iPSCs9. We selected Dppa2
because its ChIP-MS proﬁle was unusual for a pluripotency
inducing factor. Dppa2 had the highest emPAI score for
H3K4me3 but a low H3K27ac ratio, suggesting it binds
predominantly to promoters with low activity (Fig. 4a). This is
different for other pluripotency-inducing factors, such as Oct4
and Esrrb, which predominantly bind moderately active
enhancers (Fig. 3b). To identify the genome-wide binding sites
of Dppa2, we established an ESC line that expressed V5-tagged
Dppa2 and we performed anti-V5 Dppa2 ChIP and sequenced
the precipitated genomic DNA (ChIP-seq). We veriﬁed that
V5-Dppa2 binds to the promoters of Syce1 and Nkx2–5
(Fig. 4b,c), the only known Dppa2 genomic binding sites36,
which suggested that our V5-Dppa2 ChIP identiﬁed bona-ﬁde
Dppa2-binding sites. Dppa2-binding sites had the highest
genome-wide association with H3K4me3, whereas the
association with H3K27ac (Fig. 4a) is lower than that of Oct4
and Esrrb (Fig. 3a). Subsequently, we investigated the presence of
Dppa2 at promoters and enhancers in mouse ESCs. We found
that Dppa2 binds promoters but is absent from enhancer regions
(Fig. 4d). Interestingly, Dppa2 promoter binding displayed no
correlation with H3K27ac content (Fig. 4d), a binding pattern
that otherwise was only observed with the repressor Kdm5b and
the Polycomb repressor proteins (Fig. 3b). These analyses suggest
that our Dppa2 ChIP-MS location prediction was correct and that
the binding pattern of Dppa2 is different compared with other
reprogramming factors.
As expected, Dppa2 binds the promoters of genes with a lower
median expression than other H3K4me3-marked promoters and
Oct4-bound genes in ESCs (Fig. 4e and Supplementary Dataset).
The gene expression proﬁle of Dppa2 knockout ESCs was
recently determined and it was observed that far more genes were
downregulated than upregulated, compared with wild-type
ESCs36. Dppa2 binds the promoters of nearly a quarter of
the downregulated genes but much less to promoters of the
upregulated genes (Fig. 5a,b). This suggests that Dppa2 maintains
the expression of its putative target genes (Supplementary
Table 4) by binding at their promoter. In contrast, Oct4
maintains the expression of its target genes by binding mostly
outside promoters (Supplementary Fig. 2). We ﬁnd that the
median expression of Dppa2 target genes is tenfold lower than the
median expression of Oct4 target genes in ESCs (Fig. 5c). Nearly,
all Dppa2 target genes are higher expressed in tissues other than
ESCs (Fig. 5d and Supplementary Table 4). The largest minority
of Dppa2 target genes is highest expressed in testes, but many
Dppa2 target genes have their highest expression in other tissues
(Fig. 5e and Supplementary Table 4). For Oct4, the pattern is very
different, as many Oct4 target genes have their highest expression
in ESCs (Fig. 5d,e). Considering that Dppa2 and Oct4 appear to
regulate different sets of genes, we determined the overlap in
genome-wide binding sites between classical pluripotency factors
such as Oct4, Nanog and Esrrb, and Dppa2. Whereas Oct4,
Nanog and Esrrb showed an extensive overlap in binding sites, as
previously reported3, Dppa2 showed little overlap with these
factors (Fig. 5f). In particular, the overlap of Dppa2 with Oct4
and Nanog was nearly absent. Moreover, there was no overlap
between Dppa2 target genes and Oct4 target genes (Fig. 5g).
We conclude that Dppa2 regulates a set of genes that is separate
from the set of genes regulated by the classical pluripotency
transcription factors, and not ESC speciﬁc in its expression.
Discussion
We describe here ChIP-MS, a method to predict the binding of
factors to enhancers or promoters. Our experimental setup is
straightforward and does not rely on metabolic labelling for
quantiﬁcation by MS. Nevertheless, using emPAI22 and the
simple rule that the ChIP fraction in which a factor has the
highest emPAI score decides its binding prediction, we achieved
a remarkably high percentage of correct predictions when
comparing to published ChIP-seq data. We employed
crosslinking with protein–protein crosslinker DSG, followed
by standard crosslinking with formaldehyde. We previously
used this ‘double crosslinking’ procedure to improve ChIP
efﬁciency19–21. Aside from our extended crosslinking procedure,
our ChIP-MS procedure is based on standard ChIP protocols and
MS procedures, which should facilitate its application in other
cell types.
A number of studies have been performed to screen for protein
factors that bind to individual histone modiﬁcations by using
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Figure 5 | Dppa2 target genes and their overlap with the pluripotency network. (a) Bubble plot indicating the positions of Dppa2-binding sites relative to
the transcription start site (TSS) on genes that are either upregulated Z2-fold (upper part) or downregulated Z2-fold (lower part) upon Dppa2 gene
knockout in mouse ESCs. Log2 of the fold change in expression upon Dppa2 KO is indicated on the y-axis. Distance of Dppa2-binding sites from the TSS is
indicated on the x-axis. Size of the bubbles correlates with fold difference of Dppa2 ChIP peak over control. (b) Bar diagram showing the total number of
upregulated and downregulated genes upon Dppa2 knockout and the number of these genes bound by Dppa2 within 1 kb from the TSS (grey areas). The
number of Dppa2 bound genes is also indicated as a percentage of the total number of upregulated or downregulated genes. (c) Distribution of absolute
expression levels in mouse ESCs of Dppa2 target genes and Oct4 target genes. Dppa2 target genes are bound by Dppa2 within 1 kb of the TSS andZ2-fold
downregulated upon Dppa2 knockout, Oct4 target genes are bound by Oct4 within 20 kb of the TSS and Z2-fold downregulated after 24 h of Oct4
depletion. Shown is a violin plot where the white dot indicates the median and the thick black bar indicates 50% of the genes. Log2 of the absolute
expression, derived from published RNAseq data and P-value by Mann–Whitney test are indicated. (d) Distribution of the fold change in expression of
Dppa2 target genes and Oct4 target genes in the differentiated tissue with the highest expression versus expression in mouse ESCs. Shown is a violin plot
where the white dot indicates the median and the thick black bar indicates 50% of the genes. Log2 of the fold change in expression, derived from published
RNAseq data and P-value by Mann–Whitney test are indicated. (e) Lists of tissues or cells where Dppa2 target genes (left panel) or Oct4 target genes
(right panel) are highest expressed. Tissue or cells, the number of genes (N) and fold enrichment (FE) of a tissue/cell type within Dppa2 target genes or
Oct4 target genes are indicated. The 20 tissues/cells with the highest number of gene overlap and fold enrichment are shown. (f) Venn diagram showing
the overlap of genomic binding sites in mouse ESCs of Dppa2, Nanog, Oct4 and Esrrb. (g) Venn diagram showing the lack of overlap of Dppa2 target genes
and Oct4 target genes.
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modiﬁed histone peptides37–39 or in vitro assembled modiﬁed
nucleosomes40, or identify protein factors that bind native
chromatin harbouring speciﬁc histone modiﬁcations by
conventional ChIP combined with mass spectroscopy41.
Binding to different tri-methylated lysines was assessed in these
studies, but binding to enhancer marks or activity marks, such as
the H3K4me1- or H3K27ac-marked chromatin that we
interrogated with ChIP-MS, has not been addressed yet.
Previous studies identiﬁed a number of ubiquitously expressed
factors that we also observed in our ChIPs. However, our
ChIP-MS procedure is sufﬁciently sensitive to also detect the
sequence-speciﬁc transcription factors, such as Oct4, Esrrb and
Klf5, that determine ESC identity. These factors will be different
in other cell types, which makes our procedure highly suitable to
study the changing spectrum of regulatory region-associated
factors during cell differentiation.
The list of proteins for which we predict genome localization
by ChIP-MS (Fig. 2 and Supplementary Table 1) contains factors
that play a role in a number of cellular processes, including all
levels of transcriptional regulation and chromatin organization.
ChIP-MS detected chromatin-modifying complexes with clear
location predictions, such as the BAF complex (enhancer),
Aurora kinase complex (heterochromatin), Trrap complex
(promoter), MLL complex (promoter) and Sin3 complex
(promoter). The annotation of subunits of the Polycomb
complexes PRC1 and PRC2 was more ambiguous, as PRC1 and
PRC2 bind broad areas around inactive promoters marked to a
similar extent by H3K4me3 and H3K4me1, leading to false
‘enhancer’ predictions for several PRC subunits. Fortunately,
Polycomb factors are well characterized34,42 and would therefore
be easy to recognize and treated with caution in any ChIP-MS
prediction list.
Figure 2 ranks detected factors by the activity of their bound
promoters or enhancers. To our knowledge, such an analysis has
not been performed yet and provides a read-out on an important
criterion for a large set of factors in ESCs. The ranking is based on
the H3K27ac ratio; the ratio of the H3K27ac emPAI score over
the highest of the H3K4me3 emPAI score or H3K4me1 emPAI
score, which we anticipated would be the more informative value
than the H3K27 emPAI score per se, as it compensates for the
considerable differences in ChIP-MS detection levels for different
factors. Perhaps the clearest indication that the H3K27ac ratio
performs well in differentiating factors by the activity of their
bound regions is that out of the nearly 240 factors detected by
ChIP-MS, 3 members of the family of BET proteins, including
Brd4, are among the proteins with the highest H3K27ac ratios.
Brd4 was recently identiﬁed as a functional component and
marker of ‘super enhancers’25,26, arguably the most active
enhancers in the genome of a cell. The ranking of the
chromatin-modifying complexes follows common sense. The
activating BAF chromatin remodelling complex and Trrap
histone acetylase complex have higher H3K27ac ratios than the
Sin3 repression complex and the PRC1 and PRC2 complexes. The
good performance of ChIP-MS on factors with a known genome-
wide location suggests that also the localization predicted for the
many factors without genome-wide ChIP data will in most cases
be accurate. Our data set, graphically represented in Fig. 2,
therefore provides valuable new information on the trans-
criptional network in ESCs. Importantly, ChIP-MS can detect
factors with an unusual, and therefore interesting, genome
localization that can then be further investigated, Dppa2 being
an example.
We performed our ChIP-MS experiments in ESCs. The
establishment and maintenance of pluripotency, as well as the
exit from pluripotency, is intensely studied in ESCs and
several large data sets of relevant factors for the above processes
are available. We ﬁnd that a quarter (63 factors) of the
ChIP-MS-detected factors contributes to maintaining pluripo-
tency. ChIP-MS detected Oct4, Esrrb, Klf5, Dppa2 and Mycn,
factors which, as part of a 3–4 factor mix, reprogramme somatic
cells to iPSCs4,7,8. Intriguingly, ChIP-MS predicts that these
factors do not all bind to the same type of locations on the
genome. Oct4 and Esrrb were predicted to bind moderately active
enhancers, whereas Klf5 binds to highly active enhancers. Mycn
and Dppa2 were predicted to bind to high and low activity
promoters, respectively. This suggests a division of labour
between the different factors in the reprogramming process.
We found that Dppa2 had a different ChIP-MS proﬁle
compared with other pluripotency factors and accordingly we
determined its genome-wide binding sites by ChIP-seq. Indeed,
Dppa2 turned out to be an unusual pluripotency factor. Dppa2-
binding sites and target genes do not overlap with Oct4,
suggesting that Dppa2 is not part of the classical pluripotency
circuit. Furthermore, Dppa2 target genes were found to be much
lower expressed than Oct4 target genes in ESCs and higher
expressed later in development. It is an intriguing question how
Dppa2 can be an early marker and factor for reprogramming to
iPSCs, as was recently shown9, without actually regulating
ESC-speciﬁc genes. Dppa2 was proposed as a factor that binds
target genes to maintain an active chromatin structure and
facilitate their later expression36. This epigenetic marking
hypothesis is consistent with the expression pattern of the
identiﬁed Dppa2 target genes. However, we did not ﬁnd that
genes bound by Dppa2 in ESCs were preferentially
downregulated in Dppa2 knockout lungs, using a published
gene expression set36.
In conclusion, we established here a method to annotate factors
to enhancers and promoters with different activities. ChIP-MS is
straightforward in its setup, which should facilitate its application
to other cell types and growth conditions, provided sufﬁcient cell
quantities can be obtained. We showed that ChIP-MS data add to
our knowledge and understanding of the transcriptional circuitry
that determines cell identity.
Methods
Cell lines and constructs. Mouse embryonic stem cell line CGR8 was grown
on gelatin-coated dishes without feeders in Glasgow Minimum Essential Medium
(GMEM) supplemented with leukemia inhibitory factor (LIF), 15% fetal bovine
serum, 0.25% sodium bicarbonate, 1mM glutamine, 1mM sodium pyruvate,
non-essential amino acids, 50mM b-mercaptoethanol and penicillin/streptomycin,
as previously described19. The coding sequence for Dppa2 was ampliﬁed from
mouse ES cell cDNA and cloned with an N-terminal V5-tag into a pPyCAG-driven
expression vector. CGR8 cells were transfected with the V5-Dppa2 expression
vector using Lipofectamine 2,000 (Invitrogen), clones were selected with 1 mgml 1
puromycin (Sigma) and stable expression of V5-tagged Dppa2 tested by western
blot analysis with anti-V5 antibody (1:2,000; Invitrogen).
ChIP-MS procedure. For each histone modiﬁcation ChIP, 300 106 ESCs were
used. For chromatin preparation, cells were washed on plate three times with PBS
and incubated with 2mM DSG (Thermo Scientiﬁc) in PBS for 45min at room
temperature. Subsequently, ESCs were washed in PBS three times, 0.1 volume of
11% formaldehyde (Merck) in 50mM HEPES-KOH (pH 7.5), 100mM NaCl,
1mM EDTA, 0.5mM EGTA was added, mixed and incubated for 12min at room
temperature, washed two times in 4 C PBS and collected by centrifugation. All
subsequent steps were performed on ice with pre-cooled buffers. Cell lysis was
performed as described43. In brief, cells were collected and resuspended in LB1
(50mM HEPES-KOH, pH 7.5, 140mM NaCl, 1mM EDTA, 10% glycerol, 0.5%
NP-40, 0.25% Triton X-100). After 10min of incubation, cells were pelleted by
centrifugation and resuspended in LB2 (10mM Tris-HCl, pH 8.0, 200mM NaCl,
1mM EDTA, 0.5mM EGTA). After 10min of incubation, cells were pelleted
and resuspended in 3ml of freshly prepared LB3 (10mM Tris-HCl, pH 8.0,
100mM NaCl, 1mM EDTA, 0.5mM EGTA, 0.1% Na-deoxycholate, 0.5%
N-lauroylsarcosine) and sonicated on a Soniprep 150 (MSE), 27 cycles 15 s on, 45 s
off on amplitude 7. After sonication, enriched DNA fragment size was conﬁrmed to
be between 200 and 1,000 bp. 300 106 ESCs yielded approximately 10mg
chromatin (as measured by DNA content).
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Antibodies used in the different histone modiﬁcation ChIPs or GFP control
ChIP are against H3K4me1 (ab8895, Abcam), H3K4me3 (ab8580, Abcam),
H3K27Ac (ab4729, Abcam), H3K9me3 (ab8898, Abcam) and GFP (sc8334,
Santa Cruz Biotechnology). To prevent immunoglobin elution and subsequent
interference with the MS analysis, 50 mg antibodies were crosslinked to 500 ml
Protein A magnetic bead solution (15mg beads, Life Technologies) with Dimethyl
Pimelimidate (Sigma). Crosslinked antibody–bead complexes were equilibrated in
LB3 buffer and subsequently blocked with 0.5mgml 1 BSA (New England
Biolabs) and 0.2mgml 1 sonicated salmon sperm DNA (Stratagene) for 1 h. The
antibody–bead mixture was rotated overnight with B10mg chromatin at 4 C.
Beads were transferred to 1.5ml no stick tubes (Alpha laboratories) and washed
ﬁve times for 5min in RIPA buffer (50mM HEPES-KOH (pH 7.6), 500mM LiCl,
1mM EDTA, 1% NP-40, 0.7% Na-deoxycholate). After washing, the beads were
boiled for 35min at 95 C in 2 SDS sample buffer (100mM Tris-HCl (pH 6.8),
200mM DTT, 4% SDS, 20% Glycerol, 0.2% Bromophenol blue) and supernatant
was transferred to a fresh tube. ChIP-MS samples were run on 10% precast
SDS–PAGE gels (NuPage Invitrogen) and stained with colloidal Coomassie stain
(Invitrogen). Gel lanes were sliced, in-gel digested with trypsine to yield peptides
and proteins identiﬁed by analyses on an LQT-Orbitrap mass spectrometer
(Thermo), as described21. A detailed protocol for the ChIP-MS procedure can be
found at http://www.nature.com/protocolexchange/. For western blot analyses,
ChIP samples were separated on a 4–12% polyacrylamide gel (Novex) and
nitrocellulose blots probed with antibodies against the used histone modiﬁcations
(see above, 1:500 dilution, pan histone H3 antibody (Abcam 1791, 1:1,000 dilution)
and Nanog (Cosmo Bio Ltd., 1:2,000 dilution). Non-cropped versions of the
western blot panels in Fig. 1d can be found in Supplementary Fig. 3.
ChIP-MS inclusion and prediction criteria. Two independent ChIPs were
performed for each tested histone modiﬁcation and for GFP, as control ChIPs,
and analysed by MS. For inclusion into the ChIP-MS list of identiﬁed proteins
(Supplementary Tables 1 and 2), factors needed to be identiﬁed by MS with a
Mascot score of 50 or higher in at least one histone modiﬁcation ChIP. A Mascot
score of at least 45 in any of the other ChIPs was annotated in the ChIP-MS list. In
case of Mascot scores between 45 and 60, individual peptide MS/MS spectra were
checked manually and interpreted as valid identiﬁcations or discarded. In addition,
the Mascot programme was used to determine the Mascot peptide signiﬁcance
threshold (Po0.05) in the ChIP-MS samples. Signiﬁcance thresholds were
H3K4me3 (Experiment 1); Mascot score 28, H3K4me3 (Experiment 2); Mascot
score 28, H3K4me1 (Experiment 1); Mascot score 28, H3K4me1 (Experiment 2);
Mascot score 28, H3K27ac (Experiment 1); Mascot score 28, H3K27ac (Experiment
2); Mascot score 28, H3K9me3 (Experiment 1); Mascot score 28, H3K9me3
(Experiment 2); Mascot score 29, GFP (Experiment 1); Mascot score 28, GFP
(Experiment 2); Mascot score 28. For inclusion into the ChIP-MS list
(Supplementary Tables 1 and 2), protein identiﬁcations had to be based on peptides
with a Mascot score at or above the Mascot peptide signiﬁcance threshold of the
sample in which the peptides were observed. For assessment of the quantity of the
identiﬁed proteins in the ChIP-MS samples, we used emPAI a calculation method
based on the number of peptide spectra identiﬁed by MS, normalized for the
number of peptides that theoretically should be identiﬁable for that protein22
(to compensate for large proteins, which likely have more MS peptides). Inclusion
into the ChIP-MS list required an at least ﬁvefold higher average emPAI score in
the ChIPs for at least one histone modiﬁcation compared with any of the anti-GFP
control ChIPs. Inclusion into the ChIP-MS list further required a factor to have an
at least threefold higher average emPAI score in the two ChIPs for one histone
modiﬁcation compared with the two ChIPs for one or more of the other histone
modiﬁcations, to exclude factors that bind chromatin indiscriminately of the tested
histone modiﬁcations. Cytoskeletal and cytoplasmic proteins were excluded.
Average emPAI scores were calculated from the two independent ChIP-MS
experiments. Localization prediction was according to the following criteria;
highest average emPAI score in H3K4me3 ChIP samples gives ‘promoter’
prediction, highest average emPAI score in the H3K4me1 ChIP samples gives
‘enhancer’ prediction, highest average emPAI score in the H3K9me3 ChIP samples
gives ‘heterochromatin’ prediction. In case, average emPAI scores for the
H3K4me3 and H3K4me1 ChIP samples were equal, the prediction was ‘promoter’.
The H3K27ac ratio of a factor is deﬁned as the ratio of its average H3K27ac emPAI
score over the average H3K4me3 emPAI score or average H3K4me1 emPAI score,
whichever one is the highest.
ChIP and sequencing. Anti-V5 ChIPs were performed as described21. For
V5-Dppa2 ChIP, CGR8 ESCs stably expressing V5-Dppa2 (see above) were used,
for the control ChIP, the parental CGR8 parental ESC line was used. For each
ChIP, 100 106 ESCs were used. Precipitated DNA was analysed by quantitative
PCR or used for library generation followed by next-generation sequencing on an
Illumina Genome analyser, as described20.
Data analysis. Sequences with low complexity that are unlikely to map uniquely
to the genome were removed from the Dppa2 ChIP-seq, modiﬁed ChIP-seq
experiments for the used histone modiﬁcations and published ChIP-seq data sets
(Supplementary Table 5), using prinseq-lite with the dust method with 7 as
threshold44. The remaining sequences with a Phred scoreo70 were mapped to the
mm9 reference genome using Bowtie45 v0.12.7, where we used a seed length of
36 in which we allowed a maximum of two mismatches. If a read had multiple
alignments only the best matching read was reported. Duplicated reads were
removed. MACS46 v1.4.2 was used for peak calling of Esrrb, Nanog, Oct4, Polr2a,
P300, H3K4me1 and H3K4me3 using default settings. ChIP-seq data sets with
multiple replicates were merged. For peak calling the Polr2a, P300, H3K4me1,
H3K4me3 ChIP-seq data sets, the sequenced input was used as control.
For peak calling Esrrb, Nanog and Oct4, the GFP ChIP was used as a control
(Supplementary Table 5). For Dppa2, peak calling, we provided MACS1.4.2
with a shift size of 75 base pairs. Peaks with a P-valuer1 10 10 were retained
for Dppa2, Oct4, Nanog, Polr2a, H3K4me3, H3K4me1 and sites with a
P-valuer2 10 10 for Esrrb and P300. For Dppa2, only peaks with at least 100
aligned reads were retained. Dppa2, Oct4, Nanog and Esrrb peaks were considered
to overlap if their peak summit was within 125 base pairs of each other. Venn
diagrams, violin plots and bubble plots were created in R using the VennDiagram,
vioplot and ggplots2 packages, respectively. To calculate the overlap between the
mapped reads from the modiﬁed ChIP-seq experiments for H3K4me3, H3K4me1,
H3K27ac and promoters or enhancers. Promoters were deﬁned as the regions from
 1 to þ 1 kb of the summits of a signiﬁcant RNAPol2-binding sites (Polr2a)
within 1 kb of a transcription start site (TSS). Enhancers were deﬁned as the
regions from  1 to þ 1 kb of the summits of a signiﬁcant P300-binding sites that
were not within 1 kb of a TSS. The sequencing proﬁles of the conventional ChIP
and modiﬁed ChIP for the used histone modiﬁcations and the Dppa2 ChIP-seq
experiments (Figs 1g and 4c and Supplementary Fig. 1) were created in the IGV
browser47.
Genome-wide correlation. To calculate the genome-wide correlation between the
published histone modiﬁcation ChIP-seq data sets and the protein factors, we
divided the entire genome in bins of 1,000 base pairs and calculated reads per
million (RPM) for all bins in all data sets. The input was subtracted. For each
histone modiﬁcation and protein factor, we selected the 4,000 bins with the highest
RPM. A uniﬁed list was created for each individual protein factor, containing the
selected bins of the four used histone modiﬁcations and that of the protein factor
itself. The Spearman correlation coefﬁcients of the protein factor with the different
histone modiﬁcations were calculated from this list. To calculate the correlations
between conventional and modiﬁed ChIP-seq experiments for the used histone
modiﬁcations, we used a uniﬁed list that included the 4,000 bins with the highest
RPM for each conventional and modiﬁed ChIP-seq experiment.
Heatmaps. To assign promoter regions, H3K4me3 peak summits, as determined
by MACS (see above) were required to be within 1 kb range of a TSS, resulting in
12,913 promoter regions. To assign enhancer regions, H3K4me1 peak summits
were ﬁltered against the presence of H3K4me3 signal in a region from
 4.1 andþ 4.1 kb around the H3K4me1 peak summit, resulting in 30,564
enhancer regions. Promoters were sorted for number of H3K27ac reads present in
the central 2 kb of the promoter region. Enhancers were sorted for the number of
H3K27ac reads in the central 8.2 kb of the enhancer region, to also include broad
enhancers. For both promoters and enhancers, we displayed a region from  4.1 to
þ 4.1 kb around the peak summits, divided into 51 bins of 160 bp each. Promoter
and enhancer heatmaps for each protein factor or histone modiﬁcation were
normalized by calculating the RPM based on the sum of all reads found in the
displayed promoter and enhancer region for that factor.
Expression of Dppa2 and Oct4 target genes. Dppa2-bound genes contained a
MACS-called Dppa2 peak (see above) within 1 kb from the TSS. Dppa2 target
genes were deﬁned as Dppa2-bound genes with at least twofold difference in
expression in Dppa2 knockout ESCs, compared with wild-type ESCs and an
adjusted P-value of r0.10, in a Dppa2 knockout microarray data set31. The
GEO2R script, as provided by the authors on the Gene Expression Omnibus
(GEO), was used to calculate fold change in expression and adjusted P-value for
each probe. Multiple probes to the same gene were aggregated by taking the
average fold change. Oct4-bound genes contained a MACS-called Oct4 peak (see
above) within 20 kb from the TSS. Oct4 target genes were deﬁned as Oct4-bound
genes with at least twofold difference in expression between 24 and 0 h after Oct4
knockdown48 in ZHBTc4 ESCs that have their only intact Oct4 gene under
doxycycline control. The used microarray data set48 was already normalized by the
authors. A published RNA sequencing data set consisting of two replicates49
was used to calculate the mean expression of Dppa2- or Oct4-bound genes and
Dppa2- or Oct4-target genes. Both replicates were mapped against mouse reference
NCBIM37.67 using Tophat50 v2.0.11 with default settings and a segment length of
20. The aligned exon reads were counted and normalized using Bioconductor
DESeq2 package in R. Replicates were normalized by dividing the counts by their
size factors. The expression level per gene was calculated by taking the average of
both replicates and calculating the reads per kb for each gene. To calculate the fold
change of Dppa2- and Oct4-target genes in differentiated tissues over ESCs, we
used the BioGPS mouse MOE430 Gene Atlas51. The same database was used to
determine the tissue or cell line in which the Dppa2 and Oct4 target genes were
highest expressed.
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